The Organicell Regenerative Medicine Inc (OTCMKTS:OCEL) stock was one of the notable movers on Wednesday and ended the day with gains of as much as 3% after it provided a significant update.
Trading Data
On Wednesday, OCEL stock moved up by 2.61% to $0.0294 with 744k shares, compared to its average volume of 1.83 million shares. The stock has moved within a range of $0.0275 – 0.0340 after opening trade at $0.0323.
Organicell Regenerative Medicine Inc. Provides Updates of Clinical Trial Activities
The clinical stage biopharmaceutical firm provided the updates in relation to a slew of Investigational New Drug Applications as well as clinical trials related to Zofin, its flagship product. Zofin is a product that is meant for helping patients in retaining those microRNAs which are present naturally in the body. It should be noted that the product consists of as many as 300 growth factors.
Organicell Regenerative Medicine announced that up until yesterday it had managed to get a number of Investigational New Drug and emergency Investigational New Drug approvals from the United States Food and Drug Administration for the product.
It goes without saying that the update was an important one and more importantly, the updates were positive. In light of the announcement, there was a wave of optimism about the prospects of the stock among investors as well and the stock experienced a rally. It will now be interesting to follow the stock and see if it can add to its gains.
Technical Data
OCEL stock is trading below the 20-Day and 50-Day Moving averages of $0.0390 and $0.0525 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.1043. The stock is down 52% in the past month.
